Ribo Biotechnology

Suzhou Ribo Life Science is a leading clinical-stage biotechnology company specializing in the development of RNA interference (RNAi) technologies and oligonucleotide therapeutics. Founded in 2007 and headquartered in Suzhou, China, the company has established a vertically integrated platform covering the entire lifecycle of siRNA drugs, from discovery to commercialization. Its proprietary RiboGalSTAR platform enables efficient liver-targeted delivery, supporting a robust pipeline in cardiovascular, metabolic, renal, and liver diseases. Ribo has formed significant global partnerships, including a major collaboration with Boehringer Ingelheim and licensing agreements with Madrigal Pharmaceuticals and Qilu Pharmaceutical. The company successfully listed on the Hong Kong Stock Exchange in January 2026.